| Description |
Through clinical trials and genetic research at our center, we aim to create a polygenic risk score model specific to the Chinese population for prostate cancer. We will also apply for patents and pursue commercial transformation to address major clinical issues such as overdiagnosis and overtreatment of prostate cancer. This includes: (1) reducing the rate of excessive biopsies; (2) decreasing the missed diagnosis rate of high-grade or high-risk (lethal) prostate cancer, especially in the gray zone of prostate-specific antigen (PSA) levels between 4-10 ng/mL; (3) establishing testing standards and reference values in China, which will guide the formulation of clinical diagnosis and treatment guidelines in China; (4) conducting large-scale multi-stage genome-wide association studies and subsequent molecular genetic research to validate and explore the biological mechanisms of known or unknown single nucleotide polymorphisms (SNPs) related to the risk of prostate cancer development in the Chinese population, and identifying risk stratification markers for managing prostate cancer patients. |
